301239.SZ
301239.SZ
CNE100005GX3
PRYK
Loading chart...

Company Profile

Bright Eye Hospital Group Co., Ltd., together with its subsidiaries, operates ophthalmic medical institutions in China. The company offers ophthalmic diagnostic and treatment services, including refractive surgery, medical optometry and glasses fitting, cataract surgery, glaucoma treatment, strabismus and amblyopia, pediatric ophthalmology, fundus diseases treatment, oculoplastic surgery, lacrimal duct surgery, and corneal diseases treatment, as well as low vision and visual rehabilitation. It is also involved in medical, hospital, and investment management; ophthalmological research; sale of medical instruments and eyeglasses; cultural propagation; engineering renovation; and technology development. The company was formerly known as Chengdu Bright Eye Hospital Group Co., Ltd. and changed its name to Bright Eye Hospital Group Co., Ltd. in June 2025. Bright Eye Hospital Group Co., Ltd. was founded in 2005 and is headquartered in Chengdu, China.

Related stocks

2273.HK
2273.HK • China
GUSHENGTANG
26.74 HKD
720.44M USD 1Y -15.9%
1951.HK
1951.HK • China
JXR
2.29 HKD
735.35M USD 1Y -15.8%
6078.HK
6078.HK • China
HYGEIA HEALTH
9.61 HKD
737.5M USD 1Y -31.7%
002219.SZ
002219.SZ • China
NEW JOURNEY
2.11 CNY
1.09B USD 1Y -6.6%
NEPHROPLUS.NS
NEPHROPLUS.NS • India
NEPHROCARE HEALTH SERV L
616.4 INR
640.47M USD
2373.HK
2373.HK • China
BEAUTYFARM MED
18.08 HKD
570.59M USD 1Y -50.1%
301267.SZ
301267.SZ • China
Huaxia Eye
15.16 CNY
1.91B USD 1Y -24.3%
600763.SS
600763.SS • China
TOPCHOICE MEDICAL CORPORATION
33.8 CNY
2.25B USD 1Y -24.3%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
54.4% p.a.
Max Drawdown (5Y)
-79.2%
Sharpe Ratio (5Y)
-0.26
Beta Factor
0.65
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
🔴 High valuation risk: Avg P/E of 391.6 (Elevated multiple compression risk)
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (54.4% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -79.2% in the extended horizon.
ende